P05-03 Photobiomodulation-induced Nrf2 partially controls the inflammatory response in keratinocytes

Salman, S.; Guermonprez, Cyprien; Declercq, L.; Kerdine-Römer, Saadia

doi:10.1016/j.toxlet.2022.07.312

Cited by 1 publication

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, 590 and 830 nm light downregulated the expression of inflammatory mediators (S100A9 and p65) in a mouse model of rosacea 49 . Other studies have corroborated the hypothesis of the anti‐inflammatory action of PBM, such as by the reduction in TNF‐α, IL‐6, and IL‐8 mRNA and Nrf2 pathway stimulation in previously stressed human keratinocytes after irradiation with red (660 nm, 3 J/cm 2 , 12 ± 4 mW/cm 2 ) and green (520 nm, 3 J/cm 2 , 12 ± 4 mW/cm 2 ) light 63 . Besides, PBM stimulated collagen production in in vitro models 64–66 and in clinical trials.…”

Section: Discussionmentioning

confidence: 67%

“…49 Other studies have corroborated the hypothesis of the anti-inflammatory action of PBM, such as by the reduction in TNF-α, IL-6, and IL-8 mRNA and Nrf2 pathway stimulation in previously stressed human keratinocytes after irradiation with red (660 nm, 3 J/cm 2 , 12 ± 4 mW/cm 2 ) and green (520 nm, 3 J/cm 2 , 12 ± 4 mW/cm 2 ) light. 63 Besides, PBM stimulated collagen production in in vitro models [64][65][66] and in clinical trials. Researchers have reported a significant reduction in wrinkles when using amber and red light.…”

Section: Author Yearmentioning

confidence: 98%

See 1 more Smart Citation

Photobiomodulation for melasma treatment: Integrative review and state of the art

Galache,

Sena,

Tassinary

et al. 2023

Photoderm Photoimm Photomed

View full text Add to dashboard Cite

PurposePhotobiomodulation therapy (PBM) is a versatile technique for treating skin diseases. Melasma, a chronic hyperpigmentation condition, has recently been associated with vascular features and dermal photoaging and poses significant management challenges. We review the recent literature on melasma etiology and the evidence supporting PBM as a therapeutic modality for melasma treatment.MethodsWe conducted a comprehensive literature search in three different databases from May to August 2023, focusing on studies published in the past 10 years. The inclusion criteria comprised full‐text studies investigating low‐power lasers and/or light‐emitting diodes (LEDs) in in vitro or in vivo models, as well as clinical trials. We excluded studies discussing alternative melasma therapies or lacking experimental data. We identified additional studies by searching the reference lists of the selected articles.ResultsWe identified nine relevant studies. Clinical studies, in agreement with in vitro experiments and animal models, suggest that PBM effectively reduces melasma‐associated hyperpigmentation. Specific wavelengths (red: 630 nm; amber: 585 and 590 nm; infrared: 830 and 850 nm) at radiant exposures between 1 and 20 J/cm2 exert modulatory effects on tyrosinase activity, gene expression, and protein synthesis of melanocytic pathway components, and thus significantly reduce the melanin content. Additionally, PBM is effective in improving the dermal structure and reducing erythema and neovascularization, features recently identified as pathological components of melasma.ConclusionPBM emerges as a promising, contemporary, and non‐invasive procedure for treating melasma. Beyond its role in inhibiting melanogenesis, PBM shows potential in reducing erythema and vascularization and improving dermal conditions. However, robust and well‐designed clinical trials are needed to determine optimal light parameters and to evaluate the effects of PBM on melasma thoroughly.

show abstract

Section: Discussionmentioning

confidence: 67%